Coherus Strategy and Business Model

Executive Overview

Coherus is a U.S.-focused commercial-stage biopharmaceutical company that has been reshaping itself from a biosimilars company into a more concentrated oncology business. Founded in 2010 and headquartered in Redwood City, California, Coherus first built commercial scale through biosimilars, most notably UDENYCA, a pegfilgrastim product used to reduce infection risk in cancer patients receiving myelosuppressive chemotherapy. It later expanded into other biosimilars, including YUSIMRY and CIMERLI, before shifting strategic emphasis toward branded oncology. That pivot accelerated with the licensing of toripalimab from Junshi Biosciences, the acquisition of Surface Oncology, and the U.S. approval of LOQTORZI for nasopharyngeal carcinoma in 2023. As of Coherus’s FY2024 reporting, the company was still economically influenced by its legacy biosimilars portfolio, but its strategic center of gravity had moved toward oncology commercialization, immuno-oncology pipeline development, portfolio simplification, and balance-sheet repair. With FY2024 revenue of #N/A, Coherus remained a relatively small but fully operating biotech platform whose future value creation depended less on being a broad biosimilars player and more on whether it could successfully turn a focused oncology portfolio into a durable specialty business.

Coherus at a Glance

Logo
Common name	Coherus
Full legal name	Coherus Oncology, Inc.
Headquarters	Redwood City, California, United States
Ownership	Public company
Ticker	CHRS
Exchange	NASDAQ
Market Cap	$229.83M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2010; initial public offering in 2014; FDA approval of UDENYCA in 2018; licensing of toripalimab from Junshi Biosciences; acquisition of Surface Oncology in 2023; FDA approval of LOQTORZI in 2023; oncology-focused portfolio reshaping in 2024 and 2025
Industry or industries	Biopharmaceuticals; oncology therapeutics; biosimilars
Key products or services	LOQTORZI, UDENYCA, YUSIMRY, CIMERLI, and a clinical-stage immuno-oncology pipeline
Geographic footprint	Primarily U.S. commercial operations, supported by global development, manufacturing, and licensing relationships
Business segments as officially reported	One reportable segment
Company website	https://www.coherus.com

1. What Is the Strategy of Coherus?

Coherus’s public filings and investor communications show a company in transition. Historically, it used biosimilars to create commercial revenue and infrastructure. By FY2024 and into 2025, management’s stated direction was much narrower: become a focused oncology company built around LOQTORZI and a small set of immuno-oncology assets, while reducing exposure to lower-return biosimilar categories and repairing the balance sheet. Using the Playing to Win framework, Coherus’s strategy can be summarized as follows.

1. 1a. What is the winning aspiration of Coherus?

   Coherus’s winning aspiration appears to be to evolve from a biosimilars-led commercial biotech into a differentiated oncology company with both marketed and pipeline immuno-oncology assets. In practical terms, “winning” does not mean matching large pharmaceutical companies in breadth. It means building enough clinical and commercial success in oncology to create a sustainable value platform.

   Coherus has not generally framed its strategy around a long-dated public revenue target. Instead, the quantitative emphasis visible in recent disclosures has been more immediate: launch execution for LOQTORZI, advancement of selected clinical programs, reduction of debt, and extension of the company’s financial runway. That is typical of a small commercial biotech where portfolio focus and capital discipline can matter as much as top-line growth.

2. 1b. Where does Coherus play?

   Coherus is not trying to play across all of biopharma. Its field of play has narrowed to specialty oncology, especially antibody-based immunotherapy and adjacent biologics where the company can use a focused U.S. commercial model. Within that, the company appears to favor areas with meaningful unmet need, relatively concentrated prescriber bases, and room for combination strategies.

   Geographically, Coherus is primarily a U.S. commercial company. While its development and manufacturing relationships are international, its real commercial battleground is the U.S. provider-administered biologics market, where reimbursement, site-of-care economics, and specialist adoption drive success. Its older biosimilars activities created the infrastructure, but management’s recent portfolio actions suggest that Coherus no longer wants to compete broadly in every biosimilar category.

3. 1c. How does Coherus plan to win?

   Coherus’s path to winning is based on focus, not scale. The company’s approach has been to acquire or license promising biologic assets, commercialize a limited number of products in the U.S., and avoid the fixed-cost burden of trying to behave like a fully integrated large pharma company. LOQTORZI gives Coherus a branded oncology anchor, while the pipeline from Surface Oncology and other business-development efforts is meant to create follow-on value.

   In biosimilars, Coherus had to compete through market access, contracting, and reliable supply in highly price-competitive markets. In oncology, the formula is different. Here the company is trying to win through clinical differentiation, focused specialist selling, medical affairs credibility, and capital allocation discipline. The strategy implicitly recognizes that Coherus is unlikely to outspend larger oncology players; it has to be more selective instead.

4. 1d. What capabilities must Coherus have in place?

   To execute this strategy, Coherus needs a specific set of capabilities: strong business development and licensing judgment, biologics regulatory and chemistry-manufacturing-controls expertise, disciplined clinical development, specialty oncology commercialization, payer and reimbursement management, and reliable third-party manufacturing oversight.

   Equally important is the ability to integrate externally sourced assets. Coherus’s model depends less on a giant internal discovery engine and more on identifying assets that can fit into a focused commercial and clinical portfolio. That requires portfolio triage, speed in post-deal integration, and the ability to decide what not to fund.

5. 1e. What management systems does Coherus require?

   Coherus needs management systems that are tighter and more milestone-driven than those of a diversified pharmaceutical company. Public disclosures suggest the company must continuously manage launch metrics, cash runway, debt obligations, clinical-development gates, quality systems, and partner governance. Because manufacturing and development are heavily partner-dependent, supplier oversight and compliance systems are strategically important, not just operationally necessary.

   The company also needs a capital-allocation system that can quickly redirect resources toward the highest expected-return programs. For Coherus, strategy execution depends on matching every major spend category to a clear portfolio thesis: commercialize the oncology assets that matter, advance only the clinical programs with the best risk-reward profile, and avoid carrying non-core businesses that consume cash without strengthening the long-term oncology platform.

2. What Are the Current Strategic Initiatives of Coherus?

As of Coherus’s FY2024 Form 10-K and subsequent company communications in 2025, the company’s strategic agenda appears to center on five concrete initiatives.

• Build LOQTORZI into a credible U.S. oncology franchise. LOQTORZI is Coherus’s most strategically important commercial oncology asset. The company has been investing in targeted launch execution, physician education, medical affairs, and market access support around its approved nasopharyngeal carcinoma indication. Because this is a specialist market rather than a broad primary-care market, adoption depends on focused account coverage, reimbursement confidence, and clinical familiarity.
• Advance the immuno-oncology pipeline around selected antibody programs. Following the Surface Oncology acquisition, Coherus has been pushing forward clinical-stage assets such as casdozokitug and CHS-114. The strategic logic is to create follow-on oncology value beyond LOQTORZI, especially in combination settings where the company can potentially use a checkpoint inhibitor backbone and build a more coherent immuno-oncology story.
• Reshape the portfolio away from lower-return biosimilar exposure. By late 2024 and early 2025, Coherus had clearly signaled that it was simplifying the company and reducing the role of non-core biosimilars. Public disclosures around the UDENYCA franchise transaction and the company’s broader repositioning indicate that management was no longer treating biosimilars expansion as the main growth engine.
• Reduce debt and strengthen liquidity. Balance-sheet repair has become a strategic initiative, not just a finance function task. Coherus has publicly tied portfolio actions to debt reduction, lower interest burden, and improved funding visibility for its oncology programs. This matters because small biopharma companies can lose strategic freedom quickly if capital structure becomes too restrictive.
• Align the organization with a narrower oncology identity. Coherus’s repositioning is organizational as well as portfolio-based. The company’s communications increasingly present Coherus as an oncology company rather than a diversified biosimilars player. That implies a different mix of talent, commercialization priorities, medical affairs activity, and investor messaging.

3. What Is the Business Model of Coherus?

Coherus’s business model is that of a commercial-stage biopharma company that develops, licenses, acquires, and sells biologic medicines. Customers do not buy a software subscription or a service contract; they buy physician-administered or specialty biologic therapies that are ordered through healthcare channels and reimbursed through medical or pharmacy benefits depending on the product.

What customers actually buy: oncology and specialty biologics. Historically, that meant products such as UDENYCA, YUSIMRY, and CIMERLI. Increasingly, the strategic focus is on LOQTORZI and future oncology assets. In provider-administered categories, the direct purchasing customers are often specialty distributors, wholesalers, hospitals, and physician practices, while the clinical end users are patients treated by specialists.

Recurring versus one-time revenue: Coherus’s revenue is repeat-driven, but not contractually recurring. A patient may receive multiple cycles of therapy, and providers reorder product regularly, so demand can be recurring in practice. But there is no subscription lock-in. Revenue durability depends on clinical adoption, reimbursement, physician confidence, and continued formulary access.

How pricing power works: pricing power is weak in biosimilars and better, though still constrained, in branded oncology. In biosimilars, price competition, rebates, and contracting heavily shape net sales. In a branded oncology product such as LOQTORZI, there is more room for value-based pricing because clinical differentiation and exclusivity matter more. Even so, reimbursement friction, guideline positioning, and treatment alternatives still limit pricing freedom.

Why business mix matters: the mix between mature biosimilars and newer oncology products changes the economics of the company. Biosimilars can produce revenue but often come with intense price pressure. Branded oncology drugs may have better long-term margin potential and strategic value, but they require launch spending, medical affairs investment, and clinical support. As a result, a company like Coherus can show revenue without yet showing strong operating leverage.

What drives gross margin, operating margin, and cash generation: gross margin is affected by manufacturing cost, royalties or license economics, product mix, and gross-to-net deductions such as rebates and discounts. Operating margin is heavily influenced by research and development and by sales-and-marketing spending on launches. Cash generation historically depended on commercial biosimilar products, particularly UDENYCA, while the oncology pivot increases near-term investment needs in exchange for potentially better long-term strategic positioning.

Revenue model: Coherus is fundamentally a product-sales biopharma company with some licensing-style economics layered in through partnerships. It is not subscription-based, freemium, or usage-based in the software sense. Its revenue model is best understood as biologics sales through specialty channels, supported by licensing, development, and commercialization agreements.

4. What Products and Services Does Coherus Sell?

Coherus sells a small number of biologic medicines and is increasingly organized around the products with the most strategic relevance to oncology.

From a revenue perspective, UDENYCA mattered most for much of Coherus’s recent history. From a strategic perspective, LOQTORZI now matters most because it represents the company’s effort to build a differentiated oncology business rather than remain a price-pressured biosimilars player.

Coherus also has clinical-stage oncology assets, most notably casdozokitug and CHS-114, that are not current revenue drivers but are strategically important because they could determine whether Coherus becomes a one-product oncology company or a broader immuno-oncology platform.

5. What Are the Key Competitors or Peers of Coherus?

Coherus’s competition is product-specific rather than uniform across the entire company. For LOQTORZI, the company competes in oncology against much larger immunotherapy players. For UDENYCA, YUSIMRY, and CIMERLI, it has historically competed in crowded biosimilars markets. That makes a peer set more useful than a single pure-play competitor list.

• Merck & Co. – Through Keytruda, Merck is the dominant benchmark in PD-1 immuno-oncology. Even where indications do not directly overlap, Merck competes for oncologist mindshare, combination-regimen positioning, and institutional access.
• Bristol Myers Squibb – Opdivo and Yervoy make Bristol Myers a major checkpoint-immunotherapy competitor and a reference point for combination-based oncology strategies.
• BeiGene – BeiGene’s PD-1 franchise, including U.S. activity around tislelizumab, makes it relevant as a China-originated immuno-oncology peer with growing global ambitions.
• Regeneron – Regeneron is relevant through Libtayo and its broader antibody-development and specialty-biologics capabilities.
• Amgen – Amgen is both an oncology supportive-care benchmark and the originator behind Neulasta, the reference product for pegfilgrastim competition.
• Pfizer – Pfizer competes in supportive-care biosimilars, including pegfilgrastim, and has much greater scale in market access and channel relationships.
• Sandoz – Sandoz is one of the most important biosimilars comparables, particularly in categories where payer access, manufacturing scale, and portfolio breadth matter.
• Celltrion – Celltrion is a significant biosimilars competitor with broad U.S. ambitions and relevance in immunology and oncology-related biologics.
• Samsung Bioepis and Organon – These companies are important comparables in adalimumab biosimilars, where commercial scale and formulary access shape outcomes more than scientific differentiation.

One nuance matters: when LOQTORZI was approved in the U.S. for nasopharyngeal carcinoma, Coherus had a more differentiated position than it ever had in biosimilars. That does not remove competition, but it changes the nature of competition from mainly price and contracting to clinical adoption, specialist education, and future label expansion.

6. What Is the Marketing Strategy of Coherus?

Coherus’s marketing strategy is targeted and specialist-led rather than mass-market. The company does not rely on broad consumer brand advertising in the way large pharmaceutical companies sometimes do. Its products are generally sold into specialist channels where physician confidence, reimbursement clarity, formulary placement, and medical-affairs support matter more than consumer awareness.

For LOQTORZI, marketing is closely tied to disease-state education, account targeting, key opinion leader engagement, and field reimbursement support. Nasopharyngeal carcinoma is a narrow market, so Coherus’s commercial challenge is not broad reach; it is identifying the right institutions and clinicians, building confidence in the regimen, and making the ordering and reimbursement process straightforward.

For biosimilars, the marketing approach has historically been more access-driven. That means contracting, trade-channel management, provider economics, and confidence in product supply often matter more than classic brand-building. In products like UDENYCA, commercial success depends heavily on payer coverage, practice purchasing behavior, and the economics of provider-administered buy-and-bill medicine.

In short, marketing is a supporting capability for Coherus, but an important one. It is less about consumer persuasion and more about specialist targeting, scientific credibility, account-level economics, and channel execution.

7. What Are the Key Customer Segments of Coherus?

Coherus’s customer base is concentrated in healthcare institutions and specialty channels rather than retail consumers.

• Community oncology practices and infusion centers – These are especially important for products such as UDENYCA and LOQTORZI, where treatment is physician-directed and reimbursement mechanics shape ordering behavior.
• Academic medical centers and major cancer hospitals – These accounts matter disproportionately for a product like LOQTORZI because rare cancers are often treated at specialized centers and because key opinion leaders can strongly influence adoption.
• Hospitals, health systems, and group purchasing structures – Institutional purchasing and formulary decisions affect uptake, especially for provider-administered biologics.
• Specialty distributors and wholesalers – These are direct commercial customers in a transactional sense because they purchase product and supply providers.
• Payers – Medicare, Medicaid, commercial payers, and pharmacy benefit managers do not always directly purchase product, but they are economically decisive because reimbursement status determines practical demand.
• Legacy specialist segments outside core oncology – Retina specialists and immunology prescribers were relevant for CIMERLI and YUSIMRY, respectively, though those categories have become less central to Coherus’s current strategic direction.

Today, Coherus is less diversified by end market than it once appeared. Its future increasingly depends on a narrower set of oncology customers and payer stakeholders, which creates both focus and concentration risk.

8. What Is the Sales Model of Coherus?

Coherus uses a specialty-biopharma sales model. It generally sells products into the U.S. healthcare system through specialty distributors, wholesalers, and targeted field teams rather than through broad retail channels. The precise channel varies by product, but much of the company’s revenue has come from physician-administered or institutionally managed therapies.

For oncology and supportive-care products such as LOQTORZI and UDENYCA, the sales model is heavily shaped by the buy-and-bill structure. Providers acquire product, administer it, and then seek reimbursement. That means Coherus has to do more than just detail physicians. It also has to support account economics, reimbursement education, inventory confidence, and trade-channel execution.

For products such as YUSIMRY, the model is more influenced by formulary positioning and pharmacy-benefit dynamics. That requires a different commercial emphasis, including payer access and contracting. One reason Coherus’s portfolio reshaping matters is that different products need different go-to-market models, and maintaining too many distinct commercial motions can dilute focus for a small company.

The channel structure affects growth and pricing directly. In concentrated specialist channels, a small company can build meaningful customer intimacy if it covers the right accounts well. But concentrated channels also mean fewer places to hide operational problems. Reimbursement friction, supply issues, or weak field execution can show up quickly in sales performance.

9. In What Geographies Does Coherus Operate?

Coherus is best understood as a U.S.-centric commercial company with globally distributed partners and suppliers. Its headquarters are in Redwood City, California, and its commercial focus is overwhelmingly on the United States. That is where its major reimbursement relationships, specialty-account coverage, and product revenue are concentrated.

Its operating footprint is broader than its sales footprint. Coherus relies on international partners and third parties for manufacturing, licensing, and some development activity. The toripalimab relationship with Junshi Biosciences is a clear example of how the company’s supply and innovation network extends beyond the United States even though its commercial engine is largely domestic.

Practically, this means Coherus is not geographically diversified in the same way a large multinational pharma company is. Its fortunes are tied mainly to U.S. market access, U.S. oncology adoption, and U.S. capital-market conditions, while operational execution still depends on a global web of manufacturing and development relationships.

10. Who Are the Owners of Coherus?

Coherus is a publicly traded company listed on Nasdaq under the ticker CHRS. As of its recent public filings, it does not appear to have a disclosed controlling shareholder. Ownership is primarily a mix of institutional investors, insiders, and public-market shareholders.

Because Coherus is a small-cap biotech, the shareholder base can shift materially over time through follow-on financing, debt-related capital actions, and changes in institutional positioning. For the most current ownership picture, investors should review the latest proxy statement and recent Schedule 13G, 13D, and Form 13F filings.

11. How Is Coherus Organized?

Officially, Coherus reports one reportable segment. That is an important clue: despite selling multiple products and managing both commercial and pipeline assets, the company is not organized for public reporting as a multi-division pharmaceutical conglomerate.

At a practical level, Coherus appears to be organized around a few core functions:

• Commercial operations – sales, marketing, market access, trade, and medical affairs for marketed products
• Research and development – clinical development, regulatory strategy, and portfolio management for pipeline assets
• Technical operations – manufacturing oversight, quality, supply-chain coordination, and external partner management
• Corporate functions – finance, legal, compliance, investor relations, and executive leadership

The company’s structure makes sense for a focused biotech using external partnerships. It is leaner than a fully integrated large pharma model, but that also means central functions must coordinate tightly across products, clinical programs, and external suppliers.

12. How Does Coherus Operate?

On a day-to-day basis, Coherus operates as a focused biopharma integrator. It acquires or licenses biologic assets, advances them through development and regulatory processes, oversees third-party manufacturing and quality systems, and commercializes approved products through specialty channels.

The operating model has five main value-creating activities:

1. Portfolio sourcing and rights management – identifying assets that fit Coherus’s strategic focus and structuring the licensing or acquisition arrangements around them.
2. Clinical and regulatory execution – running or overseeing trials, preparing submissions, interacting with regulators, and generating data that support approvals and adoption.
3. Manufacturing and supply oversight – coordinating third-party production, quality release, packaging, and distribution for biologic products that require tight control.
4. Commercial execution – working with distributors, payers, providers, and field teams to convert approvals into actual product usage.
5. Capital allocation and portfolio discipline – deciding which programs to fund, which businesses to retain, and which assets to monetize or deemphasize.

The main operational complexities are typical of a small biologics company: dependence on external manufacturers, the need for flawless quality and regulatory compliance, cold-chain logistics, reimbursement friction in provider-administered markets, and the challenge of funding commercial launches while also running clinical development.

13. What Are the Growth Opportunities for Coherus?

Coherus’s most plausible growth opportunities come from a narrower set of bets than in its earlier biosimilars phase.

• LOQTORZI penetration in its approved indication – The clearest near-term opportunity is to deepen adoption of LOQTORZI in U.S. nasopharyngeal carcinoma treatment, especially if Coherus can execute well with specialist accounts and reimbursement support.
• Additional oncology indications – If future regulatory approvals are obtained, toripalimab could support broader commercial relevance. This is an opportunity, not an accomplished fact, and depends on data, regulatory outcomes, and partner economics.
• Pipeline value creation from casdozokitug and CHS-114 – The pipeline offers potential upside if Coherus can generate compelling clinical data in selected tumor settings and turn those assets into meaningful development programs or future products.
• Focused business development – Coherus has shown that it can use licensing and acquisition to reshape the portfolio. Additional oncology in-licensing could broaden the platform if done selectively and with financial discipline.
• Commercial leverage from a more coherent oncology portfolio – A larger set of oncology assets sold through a focused specialist infrastructure could create better commercial productivity than a mixed portfolio spanning oncology, immunology, and ophthalmology.

The main constraints are equally clear: clinical-development risk, concentration in a small number of assets, competition from much larger oncology companies, manufacturing and partner dependence, and the continuing need to manage liquidity carefully. In other words, Coherus has real growth options, but they are tied to execution quality and balance-sheet flexibility.

14. What Is the History of Coherus?

Coherus was founded in 2010 by biotech executive Denny Lanfear with an initial strategic emphasis on biosimilars. The basic thesis was that high-quality biosimilar development could create a commercial biopharma company without the discovery risk profile of early-stage drug research.

The company went public in 2014, giving it access to capital needed for biosimilar development and commercialization. A major inflection point came in 2018 with the U.S. Food and Drug Administration approval of UDENYCA, Coherus’s pegfilgrastim biosimilar. UDENYCA became the company’s most important commercial product and demonstrated that Coherus could compete in complex biologics markets.

Coherus later expanded its biosimilars portfolio with products such as YUSIMRY and CIMERLI, but the U.S. biosimilars environment proved highly competitive and uneven across categories. As a result, the company increasingly turned toward oncology. That shift accelerated through the toripalimab licensing agreement with Junshi Biosciences and the 2023 acquisition of Surface Oncology, which added immuno-oncology pipeline assets.

Another milestone came in October 2023, when the FDA approved LOQTORZI for nasopharyngeal carcinoma. By 2024 and 2025, Coherus’s public messaging had become much more explicit about narrowing around oncology, simplifying the portfolio, and using transactions and cost actions to support that repositioning.

15. What Are the Key Suppliers to Coherus?

Suppliers are strategically important to Coherus because the company is not fully vertically integrated. Its filings describe heavy reliance on third parties for manufacturing, supply, development support, and logistics.

The most important supplier categories include:

• Licensing and development partners – Junshi Biosciences is especially important because toripalimab is central to Coherus’s oncology strategy.
• Contract development and manufacturing organizations – These suppliers handle key biologics manufacturing steps such as drug substance production, fill-finish, packaging, and quality testing.
• Clinical research organizations – These partners help execute clinical studies and operationalize development programs.
• Specialty logistics and cold-chain providers – Biologic products need controlled storage and transportation, making logistics reliability important.
• Trade and distribution partners – Specialty distributors and wholesalers are not just channels; they are operational partners that influence product availability and account service levels.

Supplier structure matters strategically because biologics manufacturing can be single-sourced or operationally concentrated. That creates quality, timing, and regulatory risk. For a company of Coherus’s size, a manufacturing disruption or partner issue can have an outsized effect on revenue, launch timing, or clinical development.

16. What Are the Key Brands Owned by Coherus?

Branding matters at Coherus mainly at the product level, not in the consumer-packaged-goods sense. Physician familiarity, payer recognition, and product-label clarity matter more than emotional brand marketing.

• LOQTORZI – The company’s flagship oncology brand and the clearest expression of its current strategic direction.
• UDENYCA – Historically Coherus’s most important commercial brand and the product most associated with the company’s biosimilars success.
• YUSIMRY – A biosimilar brand that reflected Coherus’s expansion into immunology, though in a very crowded market.
• CIMERLI – An ophthalmology biosimilar brand that expanded Coherus beyond oncology-related supportive care.

For Coherus, these brands function less as broad consumer franchises and more as clinical-commercial assets that need recognition within specialist prescribing and reimbursement ecosystems. That is why market access, account coverage, and product positioning matter more than mass-media brand spend.

17. How Does the Supply Chain of Coherus Function?

Coherus’s supply chain is typical of a biologics company that outsources much of its manufacturing. It starts with external production of drug substance and drug product, moves through fill-finish, quality testing, labeling and packaging, and then flows through temperature-controlled distribution into specialty channels.

Several features make the supply chain strategically important:

• Biologics complexity – Manufacturing is more sensitive than for conventional small-molecule drugs, so process control and quality release are critical.
• Cold-chain handling – Products must be stored and transported within strict temperature ranges.
• Provider-administered channel dynamics – Product has to be available when hospitals, clinics, and infusion centers need it; service failures can quickly affect prescribing behavior.
• Regulatory dependency – Any manufacturing deviation, inspection issue, or supply interruption can affect both commercial sales and development programs.

For legacy biosimilars, supply reliability and competitive cost matter heavily because price competition is intense. For LOQTORZI and future oncology assets, reliability still matters, but so do batch timing, launch readiness, and consistency in supporting a specialist field force. In both cases, Coherus’s supply chain is a major operating risk area because so much of it depends on third parties.

18. What Is the R&D Strategy of Coherus?

R&D is central to Coherus, but its model is not that of a broad discovery-driven pharmaceutical company. The company’s R&D strategy appears to be selective, externally sourced, and portfolio-disciplined. Rather than trying to maintain a very large internal discovery engine, Coherus has used licensing and acquisition to assemble assets that fit a focused oncology thesis.

The current R&D strategy has three visible elements:

• Build around immuno-oncology – LOQTORZI provides a commercial checkpoint inhibitor foundation, while programs such as casdozokitug and CHS-114 are intended to extend the company’s presence in immune-modulating oncology therapies.
• Prioritize fewer programs – Public portfolio actions suggest that Coherus is increasingly willing to narrow the number of active bets rather than spread capital broadly.
• Use combinations and differentiated biology – The strategic aim appears to be to generate assets that can matter in combination settings, where clinical differentiation may be possible even against much larger competitors.

That R&D model is attractive for a smaller company because it can reduce fixed overhead and keep management attention focused. The tradeoff is that success depends heavily on asset selection, deal quality, and smart clinical prioritization. A small number of pipeline readouts can disproportionately shape enterprise value.

19. What Is the Finance Strategy of Coherus?

Finance has become a strategic lever for Coherus rather than a back-office function. The company’s recent public actions indicate that management has been focused on reducing leverage, improving liquidity, and reallocating capital toward oncology.

The key elements of the finance strategy appear to be:

• Portfolio monetization and simplification – Coherus has used, or announced its intention to use, strategic transactions involving mature biosimilar assets to improve the balance sheet and fund the oncology transition.
• Debt reduction – Public communications have emphasized lowering debt and interest burden, which is especially important for a company with limited room for strategic missteps.
• Cash-runway management – The company needs enough liquidity to support LOQTORZI commercialization and key clinical milestones without overextending itself.
• Concentrated reinvestment – Instead of spreading capital across many commercial categories, Coherus appears to be reinvesting behind the assets and programs most aligned with its oncology thesis.

Coherus does not have the capital-allocation profile of a mature cash-return company. There is no meaningful dividend or buyback story here. The finance strategy is fundamentally about preserving strategic flexibility: keeping enough capital to prove the oncology model while avoiding the trap of supporting too many low-return businesses at once.

20. What Major Acquisitions Has Coherus Made?

Coherus has not been a serial large-scale acquirer. Its use of inorganic strategy has been more selective and more typical of small biopharma: one or two transformative deals, plus licensing transactions that are strategically as important as acquisitions.

Surface Oncology was the company’s most important acquisition in recent years. Completed in 2023, the deal added immuno-oncology pipeline assets, including casdozokitug and CHS-114, and materially strengthened Coherus’s oncology identity. Surface was important not because of revenue, but because it shifted Coherus’s future option set.

The Junshi Biosciences toripalimab transaction was a licensing deal rather than an acquisition, but strategically it belongs in the same discussion. It gave Coherus the asset that became LOQTORZI, the company’s branded oncology anchor in the U.S. market.

Portfolio reshaping through divestiture has become just as important as acquisition. By late 2024, Coherus had publicly linked actions around the UDENYCA franchise and broader biosimilars simplification to debt reduction and a sharper oncology focus. That signals a company using M&A logic in both directions: acquiring capabilities that fit the future thesis and shedding assets that no longer do.

21. How Companies Like Coherus Leverage Independent Consultants through Umbrex

Coherus is the kind of company that can benefit from highly experienced independent consultants on targeted, high-stakes projects. Umbrex has built a global community of more than 8,000 independent management consultants across more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. Companies like Coherus use Umbrex when they need that level of training and problem-solving ability, but do not need a full traditional consulting team with all of the overhead. Umbrex consultants work across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI.

For a company such as Coherus, representative projects could include:

• Oncology portfolio strategy review to prioritize LOQTORZI, casdozokitug, CHS-114, and any future in-licensed assets against capital constraints.
• Rare-disease oncology launch diagnostic for LOQTORZI, including account segmentation, treatment-center targeting, and prescribing-barrier analysis.
• Field-force sizing and territory design for a focused U.S. oncology commercial model.
• Market access and gross-to-net optimization for provider-administered biologics, including scenario modeling by channel and payer mix.
• Business-development screening and commercial diligence on adjacent immuno-oncology assets that could strengthen Coherus’s platform.
• Clinical development prioritization support, including indication sizing, competitive landscaping, and trial-sequencing choices for pipeline assets.
• Post-divestiture operating-model redesign to align corporate functions with a narrower oncology company structure.
• Supply-chain risk assessment for single-source or internationally concentrated biologics manufacturing and cold-chain distribution.
• Debt, liquidity, and cash-runway scenario modeling to support board-level capital-allocation decisions.
• Integration planning for acquired or licensed assets, including governance, milestone tracking, and cross-functional program management.